+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Advanced Therapy Medicinal Products CDMO Market Size, Share & Trends Analysis Report by Product (Gene Therapy, Cell Therapy, Tissue Engineered), Phase, Indication, Region, and Segment Forecasts, 2021-2028

  • PDF Icon

    Report

  • 100 Pages
  • December 2021
  • Region: Global
  • Grand View Research
  • ID: 5513871
The global advanced therapy medicinal products CDMO market size is expected to reach USD 12.9 billion by 2028, according to the report. It is expected to expand at a CAGR of 12.0% from 2021 to 2028. The advanced therapy medicinal products are a group of biological products for human use that involve gene therapy products, cell therapy products, and tissue-engineered products. The growth of the market is credited to the increasing clinical trials of ATMP and the rising awareness and belief among researchers regarding the benefits of advanced therapy. The COVID-19 pandemic has significantly disrupted the cell and gene therapy industry due to the complexity in the manufacturing process.



The COVID-19 pandemic has adversely affected the overall medical industry, but the pandemic boosted the operations and development of advanced therapy due to the high requirement of the products such as mesenchymal stromal cells (MSCs) for the treatment of the virus. The regulations put forward by the FDA and government authorities have created a safe environment for the healthcare workers and allowed emergency approval for the supply of essential raw materials and faster development of the vaccines and other therapy products.

Technological advancement has been a major part of tissue engineering in the last few years. This method helps to replace or restore the injured tissues and organ function. Similarly, gene and cell therapy is attracting many patients for the treatment of rare diseases, the cases of which are augmenting globally.

Advanced Therapy Medicinal Product CDMO Market Report Highlights

  • By product, the gene therapy segment held the largest revenue share in 2020 due to the rising awareness regarding the treatment and increasing number of approvals
  • Based on phase, the phase III segment captured the largest revenue share in 2020 as this phase ensures the safety and efficacy of the drug, leading to a large volume of drug requirement
  • North America led the market in 2020 and is expected to maintain its lead in the market owing to technological advancements in treatment and increasing outsourcing activities in the region. Asia Pacific is expected to witness the highest growth over the forecast period
  • The market has been characterized by intense competition owing to the presence of leading players


This product will be delivered within 1-3 business days.
Frequently Asked Questions about the Global Advanced Therapy Medicinal Products CDMO Market

What is the estimated value of the Global Advanced Therapy Medicinal Products CDMO Market?

The Global Advanced Therapy Medicinal Products CDMO Market was estimated to be valued at $5.84 Billion in 2021.

What is the growth rate of the Global Advanced Therapy Medicinal Products CDMO Market?

The growth rate of the Global Advanced Therapy Medicinal Products CDMO Market is 12.0%, with an estimated value of $12.9 Billion by 2028.

What is the forecasted size of the Global Advanced Therapy Medicinal Products CDMO Market?

The Global Advanced Therapy Medicinal Products CDMO Market is estimated to be worth $12.9 Billion by 2028.

Who are the key companies in the Global Advanced Therapy Medicinal Products CDMO Market?

Key companies in the Global Advanced Therapy Medicinal Products CDMO Market include Celonic, Bio Elpida, CGT Catapult, Rentschler Biopharma SE, AGC Biologics, Catalent, Lonza, WuXi Advanced Therapies and Minaris Regenerative Medicine.

Table of Contents

Chapter 1 Methodology and Scope
1.1 Market Segmentation & Scope
1.1.1 Product
1.1.2 Phase
1.1.3 Indication
1.1.4 Regional Scope
1.1.5 Estimates and Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.2 Volume Price Analysis (Model 2)
1.7 List of Secondary Sources
1.8 List of Primary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective - 1:
1.10.2 Objective - 2:
1.10.3 Objective - 3:
1.10.4 Objective - 4:
Chapter 2 Executive Summary
2.1 Market Outlook
Chapter 3 Advanced Therapy Medicinal Products CDMO Market: Variables, Trends, & Scope
3.1 Market Segmentation and Scope
3.2 Market Dynamics
3.2.1 Market Driver Analysis
3.2.1.1 Rising number of clinical trials for ATMP
3.2.1.2 Increasing outsourcing activities
3.2.1.3 Growing awareness of the treatment
3.2.2 Market Restraint Analysis
3.2.2.1 Stringent regulatory approvals
3.2.2.2 High cost of outsourcing
3.3 Penetration & Growth Prospect Mapping
3.4 Advanced Therapy Medicinal Products CDMO: Market Analysis Tools
3.4.1 Industry Analysis - Porter’s
3.4.1.1 Porter’s Five Forces Analysis
3.4.2 PESTEL Analysis
Chapter 4 Advanced Therapy Medicinal Products CDMO Market: Product Estimates
4.1 Market Share Analysis, 2020 & 2028
4.2 Gene Therapy
4.2.1 Gene therapy market, 2016 - 2028 (USD Billion)
4.3 Cell Therapy
4.3.1 Cell therapy market, 2016 - 2028 (USD Billion)
4.4 Tissue Engineered
4.4.1 Tissue engineered market, 2016 - 2028 (USD Billion)
4.5 Others
4.5.1 Market, 2016 - 2028 (USD Billion)
Chapter 5 Advanced Therapy Medicinal Products CDMO Market: Phase Estimates
5.1 Market Share Analysis, 2020 & 2028
5.2 Phase I
5.2.1 Phase I market, 2016 - 2028 (USD Billion)
5.3 Phase II
5.3.1 Phase II market, 2016 - 2028 (USD Billion)
5.4 Phase III
5.4.1 Phase III market, 2016 - 2028 (USD Billion)
5.5 Phase IV
5.5.1 Phase IV market, 2016 - 2028 (USD Billion)
Chapter 6 Advanced Therapy Medicinal Products CDMO Market: Indication Estimates
6.1 Market Share Analysis, 2020 & 2028
6.2 Oncology
6.2.1 Oncology market, 2016 - 2028 (USD Billion)
6.3 Cardiology
6.3.1 Cardiology market, 2016 - 2028 (USD Billion)
6.4 Central Nervous System
6.4.1 Central nervous system market, 2016 - 2028 (USD Billion)
6.5 Musculoskeletal
6.5.1 Musculoskeletal market, 2016 - 2028 (USD Billion)
6.6 Infectious Disease
6.6.1 Infectious disease market, 2016 - 2028 (USD Billion)
6.7 Dermatology
6.7.1 Dermatology market, 2016 - 2028 (USD Billion)
6.8 Endocrine, Metabolic, Genetic
6.8.1 Endocrine, metabolic, genetic market, 2016 - 2028 (USD Billion)
6.9 Immunology & inflammation
6.9.1 Immunology & inflammation market, 2016 - 2028 (USD Billion)
6.10 Ophthalmology
6.10.1 Ophthalmology market, 2016 - 2028 (USD Billion)
6.11 Haematology
6.11.1 Haematology market, 2016 - 2028 (USD Billion)
6.12 Gastroenterology
6.12.1 Gastroenterology market, 2016 - 2028 (USD Billion)
6.13 Others
6.13.1 Others market, 2016 - 2028 (USD Billion)
Chapter 7 Advanced Therapy Medicinal Products CDMO Market: Regional Analysis
7.1 Advanced Therapy Medicinal Products CDMO: Regional Market Share Analysis, 2020 & 2028
7.2 North America
7.2.1 North America Advanced Therapy Medicinal Products CDMO Market, 2016 - 2028 (USD Billion)
7.2.2 U.S.
7.2.2.1 U.S. Advanced Therapy Medicinal Products CDMO Market, 2016 - 2028 (USD Billion)
7.2.3 Canada
7.2.3.1 Canada Advanced Therapy Medicinal Products CDMO Market, 2016 - 2028 (USD Billion)
7.3 Europe
7.3.1 Europe Advanced Therapy Medicinal Products CDMO Market, 2016 - 2028 (USD Billion)
7.3.2 U.K.
7.3.2.1 U.K. Advanced Therapy Medicinal Products CDMO Market, 2016 - 2028 (USD Billion)
7.3.3 Germany
7.3.3.1 Germany Advanced Therapy Medicinal Products CDMO Market, 2016 - 2028 (USD Billion)
7.3.4 France
7.3.4.1 France Advanced Therapy Medicinal Products CDMO Market, 2016 - 2028 (USD Billion)
7.3.5 Italy
7.3.5.1 Italy Advanced Therapy Medicinal Products CDMO Market, 2016 - 2028 (USD Billion)
7.3.6 Spain
7.3.6.1 Spain Advanced Therapy Medicinal Products CDMO Market, 2016 - 2028 (USD Billion)
7.4 Asia Pacific
7.4.1 Asia Pacific Advanced Therapy Medicinal Products CDMO Market, 2016 - 2028 (USD Billion)
7.4.2 China
7.4.2.1 China Advanced Therapy Medicinal Products CDMO Market, 2016 - 2028 (USD Billion)
7.4.3 Japan
7.4.3.1 Japan Advanced Therapy Medicinal Products CDMO Market, 2016 - 2028 (USD Billion)
7.4.4 India
7.4.4.1 India Advanced Therapy Medicinal Products CDMO Market, 2016 - 2028 (USD Billion)
7.4.5 Australia
7.4.5.1 Australia Advanced Therapy Medicinal Products CDMO Market, 2016 - 2028 (USD Billion)
7.4.6 South Korea
7.4.6.1 South Korea Advanced Therapy Medicinal Products CDMO Market, 2016 - 2028 (USD Billion)
7.5 Latin America
7.5.1 Latin America Advanced Therapy Medicinal Products CDMO Market, 2016 - 2028 (USD Billion)
7.5.2 Brazil
7.5.2.1 Brazil Advanced Therapy Medicinal Products CDMO Market, 2016 - 2028 (USD Billion)
7.5.3 Mexico
7.5.3.1 Mexico Advanced Therapy Medicinal Products CDMO Market, 2016 - 2028 (USD Billion)
7.5.4 Argentina
7.5.4.1 Argentina Advanced Therapy Medicinal Products CDMO Market, 2016 - 2028 (USD Billion)
7.5.5 Colombia
7.5.5.1 Colombia Advanced Therapy Medicinal Products CDMO Market, 2016 - 2028 (USD Billion)
7.5.6 Chile
7.5.6.1 Chile Advanced Therapy Medicinal Products CDMO Market, 2016 - 2028 (USD Billion)
7.6 MEA
7.6.1 MEA Advanced Therapy Medicinal Products CDMO Market, 2016 - 2028 (USD Billion)
7.6.2 South Africa
7.6.2.1 South Africa Advanced Therapy Medicinal Products CDMO Market, 2016 - 2028 (USD Billion)
7.6.3 Saudi Arabia
7.6.3.1 Saudi Arabia Advanced Therapy Medicinal Products CDMO Market, 2016 - 2028 (USD Billion)
7.6.4 UAE
7.6.4.1 UAE Advanced Therapy Medicinal Products CDMO Market, 2016 - 2028 (USD Billion)
7.6.5 Israel
7.6.5.1 Israel Advanced Therapy Medicinal Products CDMO Market, 2016 - 2028 (USD Billion)
7.6.6 Egypt
7.6.6.1 Egypt Advanced Therapy Medicinal Products CDMO Market, 2016 - 2028 (USD Billion)
Chapter 8 Company Profiles
8.1 Strategic Framework
8.2 Company Profiles
8.2.1 Celonic
8.2.1.1 Company Overview
8.2.1.2 Financial performance
8.2.1.3 Product Benchmarking
8.2.1.5 Strategic Initiatives
8.2.2 Bio Elpida
8.2.2.1 Company Overview
8.2.2.2 Financial performance
8.2.2.3 Product Benchmarking
8.2.2.6 Strategic Initiatives
8.2.3 CGT Catapult
8.2.3.1 Company Overview
8.2.3.2 Financial performance
8.2.3.3 Product Benchmarking
8.2.3.6 Strategic Initiatives
8.2.4 Rentschler Biopharma SE
8.2.4.1 Company Overview
8.2.4.2 Financial performance
8.2.4.3 Product Benchmarking
8.2.4.6 Strategic Initiatives
8.2.5 AGC Biologics
8.2.5.1 Company Overview
8.2.5.2 Financial performance
8.2.5.3 Product Benchmarking
8.2.5.6 Strategic Initiatives
8.2.6 Catalent
8.2.6.1 Company Overview
8.2.6.2 Financial performance
8.2.6.3 Product Benchmarking
8.2.6.6 Strategic Initiatives
8.2.7 Lonza
8.2.7.1 Company Overview
8.2.7.2 Financial Performance
8.2.7.3 Product Benchmarking
8.2.7.5 Strategic Initiatives
8.2.8 WuXi Advanced Therapies
8.2.8.1 Company Overview
8.2.8.2 Financial performance
8.2.8.3 Product Benchmarking
8.2.8.5 Strategic Initiatives
8.2.9 BlueReg
8.2.9.1 Company Overview
8.2.9.2 Financial performance
8.2.9.3 Product Benchmarking
8.2.9.6 Strategic Initiatives
8.2.10 Minaris Regenerative Medicine
8.2.10.1 Company Overview
8.2.10.2 Financial performance
8.2.10.3 Product Benchmarking
8.2.10.5 Strategic Initiatives
8.2.11 Patheon
8.2.11.1 Company Overview
8.2.11.2 Financial performance
8.2.11.3 Product Benchmarking
8.2.11.5 Strategic Initiatives
List of Figures
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Commodity flow analysis
Fig. 9 Volume Price Analysis
Fig. 10 Advanced therapy medicinal products CDMO market snapshot (2020)
Fig. 11 Advanced therapy medicinal products CDMO market segmentation
Fig. 12 Market driver relevance analysis (Current & future impact)
Fig. 13 Market restraint relevance analysis (Current & future impact)
Fig. 14 Penetration & growth prospect mapping
Fig. 15 Porter’s five forces analysis
Fig. 16 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 17 Advanced therapy medicinal products CDMO market product outlook: Segment dashboard
Fig. 18 Advanced therapy medicinal products CDMO market: Product movement analysis
Fig. 19 Gene therapy market, 2016 - 2028 (USD Billion)
Fig. 20 Cell therapy market, 2016 - 2028 (USD Billion)
Fig. 21 Tissue engineered market, 2016 - 2028 (USD Billion)
Fig. 22 Others (Combined ATMPs, for example biodegradable matric or scaffold) market, 2016 - 2028 (USD Billion)
Fig. 23 Advanced therapy medicinal products CDMO market phase outlook: Segment dashboard
Fig. 24 Advanced therapy medicinal products CDMO market: Phase movement analysis
Fig. 25 Phase I market, 2016 - 2028 (USD Billion)
Fig. 26 Phase II market, 2016 - 2028 (USD Billion)
Fig. 27 Phase III market, 2016 - 2028 (USD Billion)
Fig. 28 Phase IV market, 2016 - 2028 (USD Billion)
Fig. 29 Advanced therapy medicinal products CDMO market indication outlook: Segment dashboard
Fig. 30 Advanced therapy medicinal products CDMO market: Indication movement analysis
Fig. 31 Oncology market, 2016 - 2028 (USD Billion)
Fig. 32 Cardiology market, 2016 - 2028 (USD Billion)
Fig. 33 Central nervous system market, 2016 - 2028 (USD Billion)
Fig. 34 Musculoskeletal market, 2016 - 2028 (USD Billion)
Fig. 35 Infectious disease market, 2016 - 2028 (USD Billion)
Fig. 36 Dermatology market, 2016 - 2028 (USD Billion)
Fig. 37 Endocrine, metabolic, genetic market, 2016 - 2028 (USD Billion)
Fig. 38 Immunology & inflammation market, 2016 - 2028 (USD Billion)
Fig. 39 Ophthalmology market, 2016 - 2028 (USD Billion)
Fig. 40 Haematology market, 2016 - 2028 (USD Billion)
Fig. 41 Gastroenterology market, 2016 - 2028 (USD Billion)
Fig. 42 Others market, 2016 - 2028 (USD Billion)
Fig. 43 Regional market: Key takeaways
Fig. 44 Regional outlook, 2020 & 2028
Fig. 45 North America market, 2016 - 2028 (USD Billion)
Fig. 46 U.S. market, 2016 - 2028 (USD Billion)
Fig. 47 Canada market, 2016 - 2028 (USD Billion)
Fig. 48 Europe market, 2016 - 2028 (USD Billion)
Fig. 49 U.K. market, 2016 - 2028 (USD Billion)
Fig. 50 Germany market, 2016 - 2028 (USD Billion)
Fig. 51 France market, 2016 - 2028 (USD Billion)
Fig. 52 Italy market, 2016 - 2028 (USD Billion)
Fig. 53 Spain market, 2016 - 2028 (USD Billion)
Fig. 54 Asia Pacific market, 2016 - 2028 (USD Billion)
Fig. 55 China market, 2016 - 2028 (USD Billion)
Fig. 56 Japan market, 2016 - 2028 (USD Billion)
Fig. 57 India market, 2016 - 2028 (USD Billion)
Fig. 58 Australia market, 2016 - 2028 (USD Billion)
Fig. 59 South Korea market, 2016 - 2028 (USD Billion)
Fig. 60 Latin America market, 2016 - 2028 (USD Billion)
Fig. 61 Brazil market, 2016 - 2028 (USD Billion)
Fig. 62 Mexico market, 2016 - 2028 (USD Billion)
Fig. 63 Argentina market, 2016 - 2028 (USD Billion)
Fig. 64 Colombia market, 2016 - 2028 (USD Billion)
Fig. 65 Chile market, 2016 - 2028 (USD Billion)
Fig. 66 MEA market, 2016 - 2028 (USD Billion)
Fig. 67 South Africa market, 2016 - 2028 (USD Billion)
Fig. 68 Saudi Arabia market, 2016 - 2028 (USD Billion)
Fig. 69 UAE market, 2016 - 2028 (USD Billion)
Fig. 70 Israel market, 2016 - 2028 (USD Billion)
Fig. 71 Egypt market, 2016 - 2028 (USD Billion)
Fig. 72 Strategic Framework

Companies Mentioned

  • Celonic
  • Bio Elpida
  • CGT Catapult
  • Rentschler Biopharma SE
  • AGC Biologics
  • Catalent
  • Lonza
  • WuXi Advanced Therapies
  • BlueReg
  • Minaris Regenerative Medicine
  • Patheon

Methodology

Loading
LOADING...